Your browser doesn't support javascript.
loading
Case report: primary resistance to osimertinib in erlotinib-pretreated lung adenocarcinoma with EGFR T790 M mutation.
Zheng, Lin-Peng; Chen, Li-Ying; Liao, Xing-Yun; Xu, Zi-Han; Chen, Zheng-Tang; Sun, Jian-Guo.
Afiliação
  • Zheng LP; Department of Oncology, Xinqiao Hospital, Army Medical University, Chongqing, 400037, China.
  • Chen LY; Department of Oncology, Xinqiao Hospital, Army Medical University, Chongqing, 400037, China.
  • Liao XY; Department of Oncology, Xinqiao Hospital, Army Medical University, Chongqing, 400037, China.
  • Xu ZH; Department of Oncology, Xinqiao Hospital, Army Medical University, Chongqing, 400037, China.
  • Chen ZT; Department of Oncology, Xinqiao Hospital, Army Medical University, Chongqing, 400037, China.
  • Sun JG; Department of Oncology, Xinqiao Hospital, Army Medical University, Chongqing, 400037, China. sunjg09@aliyun.com.
BMC Cancer ; 18(1): 1070, 2018 Nov 06.
Article em En | MEDLINE | ID: mdl-30400855
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Piperazinas / Inibidores de Proteínas Quinases / Adenocarcinoma de Pulmão Limite: Humans / Male / Middle aged Idioma: En Ano de publicação: 2018 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Piperazinas / Inibidores de Proteínas Quinases / Adenocarcinoma de Pulmão Limite: Humans / Male / Middle aged Idioma: En Ano de publicação: 2018 Tipo de documento: Article